Hennion & Walsh Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-32,580	Closed	-$1.09M	–	925
2025 Q1	$1.09M	Sell	32,580 -7,510	-19%	-$280K	0.05%	455
2024 Q4	$2.05M	Sell	40,090 -745	-2%	-$41.7K	0.09%	283
2024 Q3	$2.09M	Sell	40,835 -509	-1%	-$26.3K	0.1%	272
2024 Q2	$1.85M	Buy	41,344 +3,257	+9%	+$150K	0.1%	266
2024 Q1	$1.78M	Buy	38,087 +927	+2%	+$36.3K	0.1%	282
2023 Q4	$1.32M	Buy	37,160 +2,597	+8%	+$79.6K	0.08%	340
2023 Q3	$1.03M	Buy	34,563 +16,327	+90%	+$336K	0.07%	352
2023 Q2	$329K	Buy	+18,236	New	+$364K	0.02%	624

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hennion & Walsh Asset Management's CRNX Position: Q2 2025 in Review

Hennion & Walsh Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 32,580 shares — an estimated $1.09M sold.

Hennion & Walsh Asset Management first reported a position in CRNX in Q2 2023 and held it in 8 quarters. The position peaked at $2.09M in Q3 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

Hennion & Walsh Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Hennion & Walsh Asset Management sold 32,580 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $1.09M.
Hennion & Walsh Asset Management first reported a position in Crinetics Pharmaceuticals in Q2 2023 and held it in 8 quarters.
Hennion & Walsh Asset Management's Crinetics Pharmaceuticals position peaked at $2.09M in Q3 2024.
222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.